ReviewJournal of the American College of Cardiology2023
Financial Toxicity of Medical Management of Heart Failure: JACC Review Topic of the Week.
Review in Journal of the American College of Cardiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Integrating Cost into Shared Decision-Making for Heart Failure with Reduced Ejection Fraction (POCKET-COST-HF): A Trial Providing Out-of-Pocket Costs for Heart Failure Medications during Clinical Encounters.American heart journal · 2024Trial
- Review
- Article
- Clinical Effectiveness of Sodium-Glucose Cotransporter-2 Inhibitors Among Older Patients Hospitalized for Heart Failure With Reduced Ejection Fraction.Journal of the American Heart Association · 2026Article
- Design, Characteristics, and Implementation of the Financial Support for Low-Income Patients with Heart Failure Trial.JACC. Advances · 2026Article
- Contemporary Guideline-Directed Medical Therapy for Heart Failure in the United States: The EMPACE Study.Journal of the American Heart Association · 2026Observational
- Assessment of prescriber adherence to guideline-directed medical therapy for heart failure at Jimma Medical Center, Ethiopia.International journal of cardiology. Cardiovascular risk and prevention · 2026Article
- Dyadic coping experiences of young and middle-aged patients undergoing PCI for coronary heart disease and their spouses during the perioperative period: a qualitative study.Frontiers in cardiovascular medicine · 2026Article
- The association between fear of disease progression and financial toxicity in patients with chronic osteomyelitis: a cross-sectional study.Frontiers in psychology · 2026Article
- Potential profile analysis of financial toxicity and its related factors among lung cancer patients.BMC cancer · 2025Article
- Challenges Related to Out-of-Pocket Costs in Heart Failure Management.Circulation. Heart failure · 2025Review
- Atherosclerosis and the Bidirectional Relationship Between Cancer and Cardiovascular Disease: From Bench to Bedside, Part 2 Management.International journal of molecular sciences · 2025Review
- Potential of plasma biomarkers for heart failure prediction, management, and prognosis: A multiomics perspective.Heart failure reviews · 2025Review
- Sex-based disparities with cost-related medication adherence issues in patients with hypertension, ischemic heart disease, and heart failure.Journal of the American Medical Informatics Association : JAMIA · 2024Article
- National survey of patient perspectives on cost discussions among recipients of copay assistance.The oncologist · 2024Article
- Disparities in Cardio-Oncology Care Among Patients With Prostate Cancer.JACC. CardioOncology · 2024Article
- Financial Well-Being Among US Adults with Vascular Conditions: Differential Impacts Among Blacks and Hispanics.Ethnicity & disease · 2024Article
- Efficacy and Safety of Kuoxin Formula in the Treatment of Dilated Cardiomyopathy-Related Heart Failure: Study Protocol of a Randomized, Double-Blind, Placebo-Controlled, Multi-Center Clinical Trial.International journal of general medicine · 2024Article
- Heart Failure Epidemiology and Outcomes Statistics: A Report of the Heart Failure Society of America.Journal of cardiac failure · 2023 · on this mapArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Optimal medical management of heart failure (HF) improves quality of life, decreases mortality, and decreases hospitalizations. Cost may contribute to suboptimal adherence to HF medications, especially angiotensin receptor-neprilysin inhibitors and sodium-glucose cotransporter-2 inhibitors. Patients' experiences with HF medication cost include financial burden, financial strain, and financial toxicity. Although there has been research studying financial toxicity in patients with some chronic diseases, there are no validated tools for measuring financial toxicity of HF, and very few data on the subjective experiences of patients with HF and financial toxicity. Strategies to decrease HF-associated financial toxicity include making systemic changes to minimize cost sharing, optimizing shared decision-making, implementing policies to lower drug costs, broadening insurance coverage, and using financial navigation services and discount programs. Clinicians may also improve patient financial wellness through various strategies in routine clinical care. Future research is needed to study financial toxicity and associated patient experiences for HF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.